830346-47-9

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)is used as an anti-inflammatory agent for the treatment of various conditions characterized by pain and inflammation. It is particularly effective for conditions such as osteoarthritis, rheumatoid arthritis, and acute pain.
Used in Pain Management:
As a nonsteroidal anti-inflammatory drug (NSAID), levofenac is used to manage pain by reducing inflammation and the production of prostaglandins, which are responsible for pain and inflammation in the body.
Used in Various Forms:
Benzeneacetic acid, 4-fluoro-.alpha.-(1-methylethyl)-, (.alpha.S)is available in different forms, including tablets, injections, and topical gels, making it accessible for various modes of administration and patient preferences.
Used with Caution for Side Effects:
While levofenac is typically well-tolerated by most patients, it is used with caution due to potential side effects such as stomach upset and gastrointestinal bleeding, which are common with NSAIDs.

InChI:InChI=1/C13H10F4N2O2/c1-7-5-11(20)18-12(21)19(7)6-8-9(13(15,16)17)3-2-4-10(8)14/h2-5H,6H2,1H3,(H,18,20,21)

Upstream product

• 830346-46-8 N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}urea 
• 72324-39-1 5-acetyl-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 2911-21-9 2,4-dioxo-6-methyl-3,4-dihydro-2H-1,3-oxazine 
• 239087-06-0 (2-fluoro-6-(trifluoromethyl) phenyl)methanamine 
• 31111-31-6 6-methyl-2,4-bis(trimethylsiloxy)pyrimidine 
• 626-48-2 6-Methyluracil 
• 152211-15-9 (2-fluoro-6-(trifluoromethyl)phenyl)methanol 
• 91114-97-5 5-acetyl-4-hydroxy-3,6-dihydro-2H-1,3-thiazine-2,6-dione 
• 643088-07-7 2-fluoro-6-(trifluoromethyl)benzylamine hydrochloride 
• 581072-15-3 2-fluoro-6-(trifluoromethyl)benzaldehyde oxime 
• 60611-24-7 2-fluoro-6-(trifluoromethyl)benzaldehyde 
• 401-80-9 3-fluoro-trifluoromethylbenzene 
• 239087-08-2 2-(bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene 
• 5394-63-8 2,2,6-trimethyl-4H-1,3-dioxin-4-one 

Downstream Products

• 830346-48-0 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4-(1H,3H)-dione 
• 1150560-54-5 1-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-5-iodo-6-methylpyrimidine-2,4(1H,3H)-dione 
• 869984-25-8 C₂₇H₂₈BrF₄N₃O₅ 
• 869984-51-0 C₂₆H₂₆BrF₄N₃O₅ 
• 869984-30-5 C₂₈H₃₀BrF₄N₃O₅ 
• 869984-34-9 C₂₇H₂₈BrF₄N₃O₅ 
• 869984-48-5 C₂₈H₂₇BrF₄N₄O₅ 
• 869984-31-6 C₃₄H₃₅F₄N₃O₅ 
• 869984-32-7 C₃₃H₃₃F₄N₃O₅ 
• 869984-35-0 C₃₃H₃₈BrF₄N₃O₇ 
• 869984-33-8 C₃₇H₃₉F₄N₃O₇ 

Relevant academic research and scientific papers

Preparation method of olagolide intermediate

The present invention relates to a method for preparing a lacolagoli intermediate 5-bromo-1- {[2-fluoro-6-(trifluoromethyl)phenyl] methyl}-6-methyl-2,4 (1H, 3H) pyrimidinedione (compound of formula I), in particular, a compound of formula III with 2-fluor

Preparation method of elagolix intermediate

The invention relates to a preparation method of an elagolix intermediate 1-(2-fluoro-6-trifluoromethylphenyl)-6-methyl pyrimidine-2,4(1H,3H)-diketone (I). The method comprises the following steps: taking 1-(2-fluoro-6-trifluoromethylphenyl)urea (V) and acetacetate (IV) protected by ketal as raw materials, reacting in the presence of alkali to obtain a ketal intermediate (III), and converting theketal intermediate (III) into N-((2-fluoro-6-trifluoromethylphenyl)carbamoyl)-3-oxobutylamide (II); and finally, carrying out a ring closing reaction to obtain the elagolix intermediate 1-(2-fluoro-6-trifluoromethylphenyl)-6-methyl pyrimidine-2,4(1H,3H)-diketone (I). According to the invention, the initial raw materials are cheap and easily available, and ketal-protected acetoacetate (IV) is usedas the raw material, so that the generation of isomers is avoided, and the product quality is improved.

AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to an improved process for the preparation of 4- ({(1R) -2- [5- (2-fluoro- 3- methoxy phenyl) – 3 - {[ 2-fluoro- 6-(trifluoro methyl) phenyl] methyl} -4-methyl- 2,6-dioxo- 3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino) butanoic acid of formula (I) or its pharmaceutically acceptable salts. The compound of formula (I) is represented by the following structural formula.

METHOD FOR PREPARING ELAGOLIX INTERMEDIATE AND COMPOSITION THEREOF

The present invention relates to a method for preparing an intermediate (Formula IV) of sodium elagolix. The intermediate is prepared by the following route. The method has advantages of simple and safe operation, high yield, less environmental pollution, good economic effect and suitability for industrial production, wherein R represents C1-C4 substituted or unsubstituted benzyl or allyl.

Preparation method of compound containing 6-methyluracil structure

The invention discloses a preparation method of a compound containing a 6-methyluracil structure. The invention relates to the technical field of synthesis of medical intermediates and organic chemical intermediates. The method comprises the following synthesis steps of: (1) reacting ethyl carbamate serving as a compound 1 with ethyl acetoacetate serving as a compound 2 under a heating condition under the action of an organic solvent and a catalyst to generate a compound 3 that is oxazine diketone; and (2) reacting the compound 3 with a compound 4 that is 2-fluoro-6-(trifluoromethyl) phenyl) methylamine under the condition of heating, an organic solvent or no solvent to generate a compound 5, i.e., a 6-methyl-uracil substituted derivative. The method disclosed by the invention is suitablefor industrial production and relatively low in cost, and the prepared product is high in purity and yield.

Elagolix intermediate preparation method

The invention discloses an elagolix intermediate preparation method, which specially comprises: 1, preparing 1-fluoro-2-(iodomethyl)-3-(trifluoromethyl)benzene from 2-trifluoromethyl-6-fluorobenzaldehyde, an iodinating reagent and a mixed solvent under th

Substituted pyrimidine-2, 4(1H, 3H)-dione derivative and uses thereof

The invention belongs to the technical field of medicines, and relates to a substituted pyrimidine-2, 4(1H, 3H)-dione derivative and uses thereof, and a pharmaceutical composition containing the compound. The derivative and the pharmaceutical composition can be used as gonadotropin releasing hormone receptor antagonists. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and uses of the compound and the pharmaceutical composition in prevention or treatment of sex hormone dependent diseases including but not limited to prostate cancer, endometriosis, hysteromyoma, precocious puberty and the like.

Preparation method of elagolix intermediate

The invention relates to a preparation method of an elagolix intermediate (IV). The method is carried out according to the following route, and the synthetic route is short. The method has the advantages of simple and safe operation, good yield, small env

Method for synthesizing Elagolix midbody polysubstituted pyrimidine derivate through two-step method

The invention discloses a method for synthesizing an Elagolix midbody polysubstituted pyrimidine derivate through a two-step method. The method comprises the following steps that (1) (2-fluoro-6-(trifluoromethyl)phenyl)methylamine shown as a formula II re

PROCESSES TO PRODUCE ELAGOLIX

The present invention relates to a scalable process for the making of elagolix, its salts and the process of intermediate compounds.